TY - JOUR
T1 - Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
AU - Garutti, Mattia
AU - Griguolo, Gaia
AU - Botticelli, Andrea
AU - Buzzatti, Giulia
AU - De Angelis, Carmine
AU - Gerratana, Lorenzo
AU - Molinelli, Chiara
AU - Adamo, Vincenzo
AU - Bianchini, Giampaolo
AU - Biganzoli, Laura
AU - Curigliano, Giuseppe
AU - De Laurentiis, Michelino
AU - Fabi, Alessandra
AU - Frassoldati, Antonio
AU - Gennari, Alessandra
AU - Marchiò, Caterina
AU - Perrone, Francesco
AU - Viale, Giuseppe
AU - Zamagni, Claudio
AU - Zambelli, Alberto
AU - Del Mastro, Lucia
AU - De Placido, Sabino
AU - Guarneri, Valentina
AU - Marchetti, Paolo
AU - Puglisi, Fabio
N1 - Funding Information:
Funding: The consensus and eDelphi process were supported by an unconditioning contribution from Eli Lilly Italia S.p.A.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. During the past three decades, several improvements in the adjuvant treatment of hormone receptor-positive/HER2−negative breast cancer have been achieved with the introduction of optimized adjuvant chemotherapy and endocrine treatment. However, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (hIGh Risk DEfinition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormonepositive/HER2−negative early breast cancer relapse. A panel of experts in breast cancer was involved in identifying clinical, pathological, morphological, and genetic factors. A RAND consensus method was used to define the relevance of each risk factor. Among the 21 features included, 12 were considered relevant risk factors for relapse. For each of these, we provided a consensus statement and relevant comments on the supporting scientific evidence. This work may guide clinicians in the practical management of hormone-positive/HER2−negative early breast cancers.
AB - Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. During the past three decades, several improvements in the adjuvant treatment of hormone receptor-positive/HER2−negative breast cancer have been achieved with the introduction of optimized adjuvant chemotherapy and endocrine treatment. However, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (hIGh Risk DEfinition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormonepositive/HER2−negative early breast cancer relapse. A panel of experts in breast cancer was involved in identifying clinical, pathological, morphological, and genetic factors. A RAND consensus method was used to define the relevance of each risk factor. Among the 21 features included, 12 were considered relevant risk factors for relapse. For each of these, we provided a consensus statement and relevant comments on the supporting scientific evidence. This work may guide clinicians in the practical management of hormone-positive/HER2−negative early breast cancers.
KW - adjuvant
KW - breast cancer
KW - chemotherapy
KW - consensus
KW - ctDNA
KW - endocrine therapy
KW - genomic signature
KW - hormone receptors
KW - risk of relapse
KW - TNM
UR - http://www.scopus.com/inward/record.url?scp=85127791037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127791037&partnerID=8YFLogxK
U2 - 10.3390/cancers14081898
DO - 10.3390/cancers14081898
M3 - Review article
AN - SCOPUS:85127791037
SN - 2072-6694
VL - 14
SP - 1898
JO - Cancers
JF - Cancers
IS - 8
ER -